Reasons to Retain Fresenius Medical Stock in Your Portfolio for the Time Being
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 23 2025
0mins
Should l Buy NVST?
Source: NASDAQ.COM
Company Overview: Fresenius Medical Care AG & Co. (FMS) is a leading provider of dialysis products and services, with a market cap of $15.11 billion and a strong global presence, having expanded through strategic acquisitions and partnerships.
Financial Performance: FMS shares have increased by 13.3% year-to-date, outperforming the industry, with earnings expected to grow by 12.6% over the next five years, despite facing challenges from rising costs and labor market issues.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NVST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NVST
Wall Street analysts forecast NVST stock price to fall
13 Analyst Rating
5 Buy
7 Hold
1 Sell
Moderate Buy
Current: 27.070
Low
18.00
Averages
22.22
High
27.00
Current: 27.070
Low
18.00
Averages
22.22
High
27.00
About NVST
Envista Holdings Corporation is a global dental products company. The Company's diversified portfolio of solutions covers a range of dentists' clinical needs for preventing, diagnosing, and treating dental conditions as well as improving the aesthetics of the human smile. It has more than 30 dental brands, including Nobel Biocare, Ormco, DEXIS and Kerr. Its segments include Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment primarily develops, manufactures and markets dental implant systems, including regenerative solutions, dental prosthetics and associated treatment software and technologies, as well as orthodontic bracket systems, aligners and lab products. The Equipment & Consumables segment primarily develops, manufactures, and markets dental equipment and supplies used in dental offices, including digital imaging systems, software, and other visualization/magnification systems; and endodontic systems and related products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Envista Holdings Reports Strong Q1 2026 Earnings with 9.5% Core Growth
- Core Growth Performance: Envista achieved a 9.5% core growth in Q1 2026, with ortho consumables and diagnostics showing double-digit increases, despite weaker performance in China, indicating strong global demand and competitive positioning.
- Acquisition and Integration: The completion of the acquisition of Versah enhances Envista's implants platform, expected to boost growth, margins, and EPS, thereby solidifying its leadership in the medical device sector.
- Stock Buyback Program Expansion: The board authorized an additional $300 million for stock repurchases, reflecting management's confidence in future performance and a proactive strategy to enhance shareholder value through capital returns.
- Financial Outlook and Risks: Envista reaffirmed its 2026 guidance of 2% to 4% core growth, while acknowledging geopolitical and macroeconomic uncertainties, yet remains optimistic about future cash flow and profitability.
See More
Envista Releases 2026 Financial Outlook with Strong Q1 Results
- Q1 Performance Exceeds Expectations: Envista reported a Q1 non-GAAP EPS of $0.36, beating estimates by $0.05, indicating strong market performance that is likely to positively impact stock prices.
- Significant Revenue Growth: The company achieved Q1 revenue of $706 million, a 14.4% year-over-year increase, surpassing market expectations by $25.93 million, reflecting successful sales and market expansion efforts that bolster investor confidence.
- 2026 Financial Guidance: Envista maintains its 2026 core sales growth outlook at 2% to 4%, with adjusted EBITDA growth projected at 7% to 13%, demonstrating the company's confidence and stability in future growth prospects.
- Clear EPS Targets: The company anticipates adjusted diluted EPS for 2026 to be between $1.35 and $1.45, alongside nearly 100% free cash conversion, showcasing strong financial health and sustainable profitability.
See More
Envista Holdings Receives Overweight Rating
- Rating Upgrade: Envista Holdings (NVST) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor interest.
- Price Target Set: The average price target set by analysts is $28.50, suggesting potential upside for the company's stock price, which could drive short-term price increases.
- Increased Market Confidence: An overweight rating typically signifies that analysts believe the company will outperform its peers in the industry, potentially enhancing investor confidence in the company's long-term growth prospects.
- Heightened Investor Attention: With the rating upgrade, Envista Holdings may attract more institutional investor interest, thereby increasing its market liquidity and stock price stability.
See More
Three Strong Value Stocks to Consider
- OptimizeRx Earnings Growth: OptimizeRx Corporation (OPRX) holds a Zacks Rank #1, with the consensus estimate for its current year earnings rising by 12.6% over the past 60 days, indicating strong growth potential in the digital healthcare technology sector.
- Envista Profit Increase: Envista Holdings Corporation (NVST) also carries a Zacks Rank #1, and its current year earnings estimate has increased by 11.9% in the last 60 days, reflecting its sustained competitiveness in the dental products market.
- Strattec Security Growth: Strattec Security Corporation (STRT) maintains a Zacks Rank #1, with next year's earnings expected to grow by 19.3%, showcasing a robust development trend in the automotive technology sector.
- Significant Valuation Advantage: All three companies exhibit low price-to-earnings ratios, with OptimizeRx at 6.53, Envista at 17.50, and Strattec at 11.84, all below their respective industry averages, highlighting their strong investment value.
See More
Envista Holdings Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Growth: Envista achieved Q4 2025 sales of $751 million with core sales growth of 10.8%, reflecting strong performance across all business segments and further solidifying market share.
- Innovation-Driven Revenue: CEO Paul Keel highlighted that nearly $100 million in revenue came from new products launched in the past 12 months, alongside a 30% increase in trained customers in 2025, enhancing customer loyalty and competitive positioning.
- Cost Control and Buyback Program: The company reduced G&A expenses by $35 million in 2025 and initiated a $250 million share repurchase program, returning over $160 million to shareholders, demonstrating a strong commitment to shareholder returns.
- Optimistic Future Outlook: Envista projects core revenue growth of 2% to 4% and adjusted EPS of $1.35 to $1.45 for 2026, with management expressing confidence in future growth despite macroeconomic volatility and tariff uncertainties in the Chinese market.
See More
Molina Healthcare Stock Plummets 29% After Earnings Miss
- Unexpected Quarterly Loss: Molina Healthcare reported an unexpected quarterly loss, causing its stock to plummet 29% in a single day, marking the largest drop since 2012 and indicating significant challenges in profitability.
- Weak 2026 Outlook: The company issued a weak earnings outlook for 2026, which may undermine investor confidence and further pressure the stock price, reflecting market concerns about its future growth potential.
- Strong Overall Market Performance: Despite Molina Healthcare's stock decline, the Dow Jones Industrial Average surged nearly 2% on Friday, reaching a new all-time high, indicating a market preference for value stocks that may overshadow individual stock weaknesses.
- Small Caps Outperform: Small caps showed outstanding performance on Friday, with the Russell 2000 index soaring over 3%, suggesting increased investor confidence in smaller companies, contrasting sharply with Molina's performance.
See More
Envista Holdings Reports Strong Q1 2026 Earnings with 9.5% Core Growth
- Core Growth Performance: Envista achieved a 9.5% core growth in Q1 2026, with ortho consumables and diagnostics showing double-digit increases, despite weaker performance in China, indicating strong global demand and competitive positioning.
- Acquisition and Integration: The completion of the acquisition of Versah enhances Envista's implants platform, expected to boost growth, margins, and EPS, thereby solidifying its leadership in the medical device sector.
- Stock Buyback Program Expansion: The board authorized an additional $300 million for stock repurchases, reflecting management's confidence in future performance and a proactive strategy to enhance shareholder value through capital returns.
- Financial Outlook and Risks: Envista reaffirmed its 2026 guidance of 2% to 4% core growth, while acknowledging geopolitical and macroeconomic uncertainties, yet remains optimistic about future cash flow and profitability.
See More
Envista Releases 2026 Financial Outlook with Strong Q1 Results
- Q1 Performance Exceeds Expectations: Envista reported a Q1 non-GAAP EPS of $0.36, beating estimates by $0.05, indicating strong market performance that is likely to positively impact stock prices.
- Significant Revenue Growth: The company achieved Q1 revenue of $706 million, a 14.4% year-over-year increase, surpassing market expectations by $25.93 million, reflecting successful sales and market expansion efforts that bolster investor confidence.
- 2026 Financial Guidance: Envista maintains its 2026 core sales growth outlook at 2% to 4%, with adjusted EBITDA growth projected at 7% to 13%, demonstrating the company's confidence and stability in future growth prospects.
- Clear EPS Targets: The company anticipates adjusted diluted EPS for 2026 to be between $1.35 and $1.45, alongside nearly 100% free cash conversion, showcasing strong financial health and sustainable profitability.
See More
Envista Holdings Receives Overweight Rating
- Rating Upgrade: Envista Holdings (NVST) has received an overweight rating, indicating analysts' optimistic expectations for its future performance, which may attract more investor interest.
- Price Target Set: The average price target set by analysts is $28.50, suggesting potential upside for the company's stock price, which could drive short-term price increases.
- Increased Market Confidence: An overweight rating typically signifies that analysts believe the company will outperform its peers in the industry, potentially enhancing investor confidence in the company's long-term growth prospects.
- Heightened Investor Attention: With the rating upgrade, Envista Holdings may attract more institutional investor interest, thereby increasing its market liquidity and stock price stability.
See More
Three Strong Value Stocks to Consider
- OptimizeRx Earnings Growth: OptimizeRx Corporation (OPRX) holds a Zacks Rank #1, with the consensus estimate for its current year earnings rising by 12.6% over the past 60 days, indicating strong growth potential in the digital healthcare technology sector.
- Envista Profit Increase: Envista Holdings Corporation (NVST) also carries a Zacks Rank #1, and its current year earnings estimate has increased by 11.9% in the last 60 days, reflecting its sustained competitiveness in the dental products market.
- Strattec Security Growth: Strattec Security Corporation (STRT) maintains a Zacks Rank #1, with next year's earnings expected to grow by 19.3%, showcasing a robust development trend in the automotive technology sector.
- Significant Valuation Advantage: All three companies exhibit low price-to-earnings ratios, with OptimizeRx at 6.53, Envista at 17.50, and Strattec at 11.84, all below their respective industry averages, highlighting their strong investment value.
See More
Envista Holdings Reports Strong Q4 2025 Earnings and Growth Outlook
- Significant Growth: Envista achieved Q4 2025 sales of $751 million with core sales growth of 10.8%, reflecting strong performance across all business segments and further solidifying market share.
- Innovation-Driven Revenue: CEO Paul Keel highlighted that nearly $100 million in revenue came from new products launched in the past 12 months, alongside a 30% increase in trained customers in 2025, enhancing customer loyalty and competitive positioning.
- Cost Control and Buyback Program: The company reduced G&A expenses by $35 million in 2025 and initiated a $250 million share repurchase program, returning over $160 million to shareholders, demonstrating a strong commitment to shareholder returns.
- Optimistic Future Outlook: Envista projects core revenue growth of 2% to 4% and adjusted EPS of $1.35 to $1.45 for 2026, with management expressing confidence in future growth despite macroeconomic volatility and tariff uncertainties in the Chinese market.
See More
Molina Healthcare Stock Plummets 29% After Earnings Miss
- Unexpected Quarterly Loss: Molina Healthcare reported an unexpected quarterly loss, causing its stock to plummet 29% in a single day, marking the largest drop since 2012 and indicating significant challenges in profitability.
- Weak 2026 Outlook: The company issued a weak earnings outlook for 2026, which may undermine investor confidence and further pressure the stock price, reflecting market concerns about its future growth potential.
- Strong Overall Market Performance: Despite Molina Healthcare's stock decline, the Dow Jones Industrial Average surged nearly 2% on Friday, reaching a new all-time high, indicating a market preference for value stocks that may overshadow individual stock weaknesses.
- Small Caps Outperform: Small caps showed outstanding performance on Friday, with the Russell 2000 index soaring over 3%, suggesting increased investor confidence in smaller companies, contrasting sharply with Molina's performance.
See More
